The estimated Net Worth of Paul Belsky is at least $112 Tysiąc dollars as of 16 May 2014. Paul Belsky owns over 2,500 units of Heat Biologics Inc stock worth over $112,312 and over the last 11 years Paul sold HTBX stock worth over $0.
Sign up
Paul Belsky HTBX stock SEC Form 4 insiders trading
Paul has made over 1 trades of the Heat Biologics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Paul bought 2,500 units of HTBX stock worth $10,275 on 16 May 2014.
The largest trade Paul's ever made was buying 2,500 units of Heat Biologics Inc stock on 16 May 2014 worth over $10,275. On average, Paul trades about 625 units every 0 days since 2013. As of 16 May 2014 Paul still owns at least 47,190 units of Heat Biologics Inc stock.
You can see the complete history of Paul Belsky stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Paul Belsky's mailing address?
Paul's mailing address filed with the SEC is C/O 100 EUROPA DRIVE, , CHAPEL HILL, NC, 27517.
Insiders trading at Heat Biologics Inc
Over the last 11 years, insiders at Heat Biologics Inc have traded over $311,853 worth of Heat Biologics Inc stock and bought 1,805,692 units worth $1,373,576 . The most active insiders traders include Louis C Bock, Michael Kharitonov oraz John K A Prendergast. On average, Heat Biologics Inc executives and independent directors trade stock every 319 days with the average trade being worth of $582,988. The most recent stock trade was executed by John K A Prendergast on 14 May 2021, trading 35,000 units of HTBX stock currently worth $205,450.
What does Heat Biologics Inc do?
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
What does Heat Biologics Inc's logo look like?
Complete history of Paul Belsky stock trades at Heat Biologics Inc
Heat Biologics Inc executives and stock owners
Heat Biologics Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Alan Wolf J.D.,
Founder, Chairman, CEO & Pres -
Jeffrey Alan Wolf,
Founder, Chairman, CEO & Pres -
William L. Ostrander,
CFO & Sec. -
Dr. Paul W. Tebbey M.B.A., Ph.D.,
Sr. VP of Product Devel. & Portfolio Strategy -
Dr. Anthony M. Manning Ph.D.,
Chief Scientific Advisor -
Colonel George E. Peoples Jr., F.A.C.S., FACS, M.D.,
Chief Medical Advisor -
Dr. Anthony M. Manning,
Chief Scientific Advisor -
Colonel George E. Peoples Jr., F.A.C.S., M.D., FACS,
Chief Medical Advisor -
Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D.,
Chief Medical Advisor and Member of Scientific & Clinical Advisory Board -
John J Monahan,
Director -
Edward B Iii Smith,
Director -
Michael Kharitonov,
Director -
Jeffrey Alan Wolf,
Chief Executive Officer -
John K A Prendergast,
Director -
Ann A Rosar,
VP of Finance and Controller -
Robert James Jakobs,
VP Finance/Controller/Secty -
Anil K. Goyal,
VP of Business Development -
Louis C Bock,
Director -
Paul Belsky,
Director -
Timothy J Creech,
Chief Financial Officer -
Melissa Price,
VP Clinical/Regulatory Affairs -
Taylor Schreiber,
Vice President of Research -
Jeffrey Alan Orion Holdings...,
Chief Executive Officer -
Capital Management, Llc Bri...,
-
Matthew E Czajkowski,
Chief Financial Officer -
Jeff Tobin Hutchins,
CSO and COO -
William L. Ostrander,
CFO/Corp Secy